ClinicalTrials.gg
Not yet recruitingNCT06662773Updated Oct 29, 2024

Drug-Drug Interaction (DDI) Study for TQB3616

A Phase 1 interventional study of TQB3616 capsule + itraconazole and TQB3616 capsule + rifampicin in Healthy, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-29.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

To evaluate the effect of itraconazole/rifampicin on the pharmacokinetics of TQB3616 capsules.

To assess the safety of a single dose of oral TQB3616 capsules and in combination with itraconazole/rifampicin.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At the time of signing the form, the age is 18\~45 years old (including the cut-off value), both male and female;
  • Females ≥ 45kg, males ≥ 50kg, (BMI) is 19\~26 kg/m\^2 (including the critical value), BMI = weight (kg)/height\^2 (m\^2);
  • Those with normal vital signs, physical examination, clinical laboratory examination, imaging examination, 12-lead , or abnormal but no clinical significance as judged by the investigator;
  • Subject is able to comply with study procedures, voluntarily participate in this trial, and sign an informed consent form in writing.

Exclusion criteria

Exclusion Criteria:

  • Those who have suffered or are currently suffering from any clinically serious diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, genitourinary system, hematology, immunology, psychiatry and metabolic abnormalities or any other diseases that can interfere with the test results;
  • Those who have systemic/local acute infection before taking the study drug;
  • Those with a history of food or drug allergies, or allergies;
  • Those who have dysphagia or suffer from any gastrointestinal diseases that affect drug absorption at the time of screening;
  • Those who cannot accept intravenous indwelling needle puncture blood vessels to collect blood samples, or the subjects cannot tolerate venipuncture, or have a history of needle fainting or blood sickness;
  • Regular drinkers within 6 months before the first dose, that is, those who drink more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of spirits with 40% alcohol or 150 mL of wine) or those who have a positive alcohol breath test at screening;
  • History of major surgical operation (defined as difficult and complex intraoperative surgery, such as gastric and duodenal surgery, partial nephrectomy, radical resection of malignant tumor, etc.) within 3 months before the first dose, or have taken drugs or participated in other drug clinical trials;
  • Blood donation or massive blood loss (>400 mL) within 3 months before the first dose;
  • Those who have used drugs within 3 months before the first dose, or those who have a positive drug screen, or those who have a history of drug abuse within five years before screening;
  • Those who smoke more than 5 cigarettes per day within 3 months before the first dose or those who cannot stop using any tobacco products during the trial;
  • Daily consumption of excessive tea, coffee, and/or caffeinated beverages (more than 8 cups, 1 cup=250 mL) within 30 days prior to the first dose;
  • Use of any drug that inhibits or induces the hepatic metabolism of the drug within 30 days before the first dose (such as: inducers carbamazepine, dexamethasone, rifampicin, phenytoin, phenobarbital, St. John's worn, etc.); CYP3A4 inhibitors itraconazole, ketoconazole, clarithromycin, telithromycin, lopinavir, ritonavir, etc.);
  • Have taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health products within 14 days before the first dose;
  • Those who have taken a special diet (such as grapefruit) or other factors that affect the absorption, distribution, metabolism, and excretion of drugs within 7 days before the first dose;
  • Ingestion of chocolate, any caffeine-containing, or xanthine-rich food or drink 48 hours prior to the first dose;
  • Those who have special dietary requirements and cannot comply with the unified diet;
  • Pregnant or lactating women, as well as subjects and their spouses who have childbearing, or sperm donation, or egg donation plans within 3 months from signing the form to the last dose, or who cannot guarantee the use of effective during this period (taking one or more non-drug contraceptive measures during the trial);
  • Subjects who are judged by the investigator to be unsuitable to participate.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Inhibitor group

    Oral TQB3616 capsules 60 mg after a single meal on days 1 and 13; On days 10 to 21, itraconazole capsules 200mg were taken orally once a day for 12 days after meals.

    Drug: TQB3616 capsule + itraconazole

  • Experimental
    Inducer group

    180mg of TQB3616 capsules orally after a single meal on days 1 and 17; Oral administration of rifampicin capsules 600mg from day 10 to day 25 on the peritoneum once a day for 16 consecutive days, of which rifampicin capsules 600mg and TQB3616 capsules 180mg were taken at the same time after meals on the 17th day.

    Drug: TQB3616 capsule + rifampicin

Interventions

  • DrugTQB3616 capsule + itraconazole

    Drug pages: Culmerciclib · Itraconazole

    C2/4/6 inhibitors + CYP3A metabolic enzyme inhibitors

  • DrugTQB3616 capsule + rifampicin

    Drug pages: Culmerciclib · Rifampin

    C2/4/6 inhibitors + Non-specific cytochrome P450 enzyme inducer

06

What researchers measure

Primary outcomes

  1. Peak concentration (Cmax)

    Maximum plasma drug concentration

    Time frame: Before administration, 1,2,4,6,8,12,24,48,72,120,168,216 hours after administration

  2. Area under drug time curve (AUC0-t)

    Area under the plasma concentration time curve from time 0 to last time of quantifiable concentration.

    Time frame: Before administration, 1,2,4,6,8,12,24,48,72,120,168,216 hours after administration

  3. Area under drug time curve (AUC0-∞)

    Area under the plasma concentration-time curve from time 0 extrapolated to infinite time.

    Time frame: Before administration, 1,2,4,6,8,12,24,48,72,120,168,216 hours after administration

Secondary outcomes

  1. Adverse event rate

    Incidence and severity of adverse events and serious adverse events, and abnormal laboratory examination indicators.

    Time frame: From before the first administration to 26 days after the administration

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2024; primary completion for Mar 2025, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2024
First posted
Oct 29, 2024
StartEst.
Nov 2024
Primary completionEst.
Mar 2025
CompletionEst.
Jul 2025
Last update
Oct 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06662773
Responsible party
Sponsor
First posted
Oct 29, 2024
Start date
Nov 2024 (estimated)
Primary completion
Mar 2025 (estimated)
Completion
Jul 2025 (estimated)
Last update
Oct 29, 2024

Study contacts

Laichun Lu
Contact
lulaicq@163.com
138 8393 3701

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Culmerciclib · Itraconazole · Rifampin

Start the discussion